Gary Fischer
Analyst · Craig-Hallum
Okay. Thank you, Leslie, and good afternoon to everyone. I'm hearing a little bit of background noise. So Morris and Leslie, it might be good during the -- this portion of the meeting that we go on mute that we're not speaking, so. By the way, to our group, we're in different locations today. Morris is -- it's the middle of the night in China. So he's in China, and I'm in the Fremont office for AXT. So, unless he's here also in the Bay Area, so. Okay. Today, we are pleased to report that total revenue for the first quarter of 2022 was $39.7 million. That's up 5% from $37.7 million in the fourth quarter of 2021 and up 26% from $31.4 million in the first quarter of 2020. Q1 marks our 9th consecutive quarter of growth and highlights the market expansion and increasing demand for indium phosphide and gallium arsenide substrates. To break down our Q1 '22 revenue for you by product category, indium phosphide was $15.5 million, gallium arsenide was $12.0 million, germanium substrates were $4.2 million and revenue from our 2 consolidated raw material joint venture companies was $7.9 million. In the first quarter of 2022, revenue from Asia Pacific was 73%, Europe was 16%, North America was 11%. The top 5 customers generated approximately 29% of total revenue, one of which just inched over the 10% level. Our continued revenue diversity demonstrates that our growth is not overly dependent on one large customer or application. This is another factor contributing to our confidence that we have reached a point of sustainability and can outpace market growth in 2022. Non-GAAP gross margin in the first quarter was 33.8% compared with 32.4% in Q4 of 2021 and 36.9% in Q1 of 2021. For those who prefer to track results on a GAAP basis, gross margin in the first quarter was 33.6% compared with 32.2% in Q4 of 2021 and 36.8% in Q1 of 2021. Improvement in gross margin came through growing volume, a favorable product mix and a strong focus on yield improvements and manufacturing efficiencies. We continue to believe that we can get back to the 35% range later this year. Total non-GAAP operating expense in Q1 was $8.6 million. This compares with $8.1 million in Q4 of 2021 and was $7.2 million in Q1 of 2021. On a GAAP basis, total operating expense in Q1 2022 was $9.6 million compared with $9.1 million in Q4. For comparison, total GAAP operating expense was $8.0 million in Q1 of 2021, so. Non-GAAP operating profit for the first quarter of 2022 was $4.8 million. Non-GAAP operating profit in Q4 of 2021 of $4.1 million and $4.4 million in Q1 of 2021. For reference, GAAP operating profit for the first quarter of 2022 was $3.7 million, up from an operating profit of $3.0 million in Q4 of 2021 and an operating profit of $3.6 million in Q1 2021. Non-operating other income and expense for the first quarter of 2022 was a net gain of $0.3 million. This includes a gain of $1.1 million from the unconsolidated raw material companies. The full breakdown is in our press release. For Q1 2022, we had a non-GAAP net income of $4.3 million or $0.10 per share compared with $4.1 million or $0.09 per share in the fourth quarter of 2021. Non-GAAP net income in Q1 of 2021 was $4.2 million or $0.10 per share. On a GAAP basis, net income in Q1 was $3.2 million or $0.07 per share. By comparison, net income was $3.0 million or $0.07 per share in the fourth quarter of 2021 and $3.4 million or $0.08 per share in Q1 of 2021. The weighted average diluted shares outstanding in Q1 was 42.7 million. Cash, cash equivalents and investments were $44.3 million as of March 31. By comparison at December 31, that was $51.8 million. Depreciation and amortization in the first quarter was $2.0 million and capital investments were $6.3 million. Total stock comp was $1.1 million. Net inventory at March 31 was $68.8 million. Okay. This concludes the review of our quarterly financial results. Turning to our plan to list our subsidiary, Tongmei, in China on the STAR Market in Shanghai, let me give you a quick update. So the review of our application is now underway, is proceeding according to our expectations. Tongmei received a list of questions from the Shanghai Stock Exchange Review Board. This is similar to what we call a comment letter from the U.S. SEC. Our China advisers think the list was fair and reasonable, and we have provided a lengthy and detailed response. Our advisers tell us to expect another set of questions as it is normal to have more than one round of comments. And indeed, we did earlier this week, get the second set of questions, so that's positive. It was very fast turnaround, and we're pleased with that. So, as we have discussed, the process of going public on the STAR Market includes several periods of review and therefore, is a lengthy process. Tongmei does not expect to complete the IPO until the second half of this year. Before I turn the call over to Morris, I want to take a moment to address the COVID restrictions in China, which have been in the news, of course. To date, we have not had any shutdowns of our operations in Beijing, Dingxing or Kazuo. We have experienced some supply chain disruption as a result of shipment delays and supplier shutdowns relating to products we use in our manufacturing process. However, so far, we've been able to mitigate the impact with inventory on hand. We've also seen some pockets of softness where customers are on lockdown, but the demand for our products, coupled with the diversity of customers and applications that need them, have allowed us to shift our allocations to other customers or applications that remain in high demand. Like most companies, we are monitoring the situation closely. And with Morris in China, are managing through these issues with high-level attention. We remain in close contact with our customers to understand any changes in their demand expectations should those changes arise. Okay. With that, I'm going to turn the call over now to Dr. Morris Young for a review of our business and markets. Morris?